Tuesday, July 8, 2025

Finerenone Enhances Patient Outcomes and Cuts Costs for Diabetic Kidney Disease

Similar articles

Patients battling both type 2 diabetes and chronic kidney disease (CKD) have a new ally in finerenone, a treatment addition proven to extend lives and reduce expenses significantly.

Comprehensive Study Design

Utilizing the FINE-CKD model and data from the extensive FIDELITY analysis, researchers assessed the economic and health impacts of adding finerenone to the standard care regimen for CKD patients with type 2 diabetes. The study adopted a societal perspective from the Netherlands, emphasizing broader cost implications beyond direct healthcare expenses.

Subscribe to our newsletter

Impact on Health and Economics

The introduction of finerenone resulted in an average gain of 0.14 quality-adjusted life years (QALYs) per patient. More importantly, it led to lifetime savings of €2,713 per patient by mitigating renal and cardiovascular events, which are costly complications associated with CKD and diabetes.

Key Inferences:

  • Finerenone effectively reduces the frequency of severe renal and cardiovascular incidents in CKD patients with type 2 diabetes.
  • The treatment not only enhances patient quality of life but also offers substantial economic benefits by lowering long-term healthcare and societal costs.
  • There is an 83.8% probability that finerenone remains cost-effective under the willingness-to-pay threshold of €20,000 per QALY.

The robustness of finerenone’s cost-effectiveness was affirmed through sensitivity analyses, which demonstrated consistent benefits across various scenarios and uncertainties inherent in the model parameters.

Chronic diseases like CKD in diabetic patients significantly strain healthcare resources and societal finances. Addressing these challenges requires treatments that offer both clinical effectiveness and economic viability, making finerenone a promising option.

Adopting finerenone in standard treatment protocols can lead to better health outcomes for patients while concurrently easing the financial burden on healthcare systems and society. This dual advantage underscores the importance of integrating cost-effective therapies in managing chronic illnesses, ultimately fostering a more sustainable healthcare environment.

Source

You can follow our news on our Telegram, LinkedIn and Youtube accounts.


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Latest article